ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

Jen Lamppa, VP of Commercial Strategy at Inovalon, says that RWD will be held to the same scrutiny as trial data if used in ...

Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...

Certain low-risk or mature devices may see reduced trial requirements, but the broader trend is toward augmenting—not ...

Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.

On December 17, the U.S. Food and Drug Administration (FDA) finalized its long-awaited guidance on the “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices,” ...

In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...

In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, ...

Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Jo ...

The traditional process for evaluating new therapeutics may not generate the evidence that patients, clinicians, and payers need to make real-world decisions. The volume and complexity of information ...